Last reviewed · How we verify

Centers for Disease Control and Prevention, China — Portfolio Competitive Intelligence Brief

Centers for Disease Control and Prevention, China pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sabin IPV Sabin IPV marketed inactivated viral vaccine poliovirus serotypes 1, 2, and 3 Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Chaoyang District Centre for Disease Control and Prevention · 1 shared drug class
  2. Centers for Disease Control and Prevention · 1 shared drug class
  3. Federal University of Espirito Santo · 1 shared drug class
  4. International Vaccine Institute · 1 shared drug class
  5. MacroGenics · 1 shared drug class
  6. Sanofi Pasteur, a Sanofi Company · 1 shared drug class
  7. Shandong Province Centers for Disease Control and Prevention · 1 shared drug class
  8. Sinovac Biotech Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centers for Disease Control and Prevention, China:

Cite this brief

Drug Landscape (2026). Centers for Disease Control and Prevention, China — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centers-for-disease-control-and-prevention-china. Accessed 2026-05-17.

Related